Although altered expression of some enzymes of the TXN system was already observed in selected hematologic malignancies (Agrawal‐Singh et al., 2012; Sewastianik et al., 2016; Trzeciecka et al., 2015), our knowledge on the influence of these enzymes on cancer progression and response to therapy of BCP‐ALL is currently limited. The gene discussed is TXN; the disease is cancer.